CompletedNCT02181803

Elpipodect (MK-8189) Multiple Dose Study in Healthy Volunteers and Schizophrenia Participants (MK-8189-003)

Medication studyAges 18–60

The study in practice

Understand this study

This study was for healthy volunteers. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Activities: Medication described in the protocol · Placebo comparator · Medication and placebo comparator listed across study groups
Compensation: Payment and expense reimbursement have not been verified.

Study clarity

Study start dateStarted: August 5, 2014

Recruitment status: Completed
Enrollment listed in the registry: 55
Sponsor: Merck Sharp & Dohme LLC
Sponsor type: Other organization
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 1
Locations: Not clearly listed
Age range: From 18 Years to 60 Years
Official registry ID: NCT02181803
Official title: Show the full official title
A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8189 in Healthy Volunteers and in Schizophrenia Patients

Completed

Locations not listed

FAQ

Who is behind this study?

The study sponsor is Merck Sharp & Dohme LLC.

Did this study involve medication?

Yes. The study involved medication, including Elpipodect, Placebo and Base Monotherapy.

Who was this study for?

This study was for healthy volunteers. Listed age limits: 18 years to 60 years. Other eligibility criteria applied.

Explore other studies

Answer a few simple questions to explore HopeStage studies by condition, country, and situation.